Drug Resistant Avian Flu

Three patients infected with the new H7N9 bird flu have developed resistance to antiviral drug treatment, causing great concern among doctors.

Written byEdyta Zielinska
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

FLICKR, KASHIF MARDANIThe H7N9 strain of bird flu circulating in China appears to have easily developed resistance to antiviral drug treatment, according to the authors of a new study published today (May 29) in The Lancet. Three out of 14 patients treated with antiviral drugs such as Tamiflu, which had helped control infection in other flu patients, became resistant to the treatment and failed to respond.

The 14 patients studied all developed pneumonia and many required ventilators to help them breathe. Antiviral drugs such as Tamiflu were administered, and in most patients, the drugs helped reduce viral load, leading to better outcomes. However, three patients did not respond to the treatments, and two of them died. A genetic analysis of isolates from these patients showed that the virus had developed mutations that allowed it to escape the drug’s mechanism of action.

One of the three patients appeared to develop resistance after treatment with antivirals, suggesting that the mutations arose in response to treatment.

The H7N9 strain has been confirmed in 131 people and has caused 36 deaths since it was first reported, according to BBC News. “The apparent ease with which ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies